To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require the Secretary of Health and Human Services to approve a risk
evaluation and mitigation strategy for mifepristone that is identical to the strategy
previously approved, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Trade, Agriculture.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Restoring Safeguards for Dangerous Abortion Drugs Act.
- Section id543a8589c8014fad91e25f8c047b327b: 2. Definition In this Act, the term covered medication means mifepristone, also known by the brand names, Mifeprex and Korlym, and the developmental code name,...
- Section ida78e09742fbf4bc0a8ba48a9ee626448: 3. Mifepristone REMS Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services shall— withdraw approval of the...
- Section id178d0c8d8cd943d0b50118e7e9e1fc4e: 4. Federal tort for harm to women caused by abortion drugs In this section, the term covered entity means a telehealth provider, pharmacy, or any other person...
- Section id4ee920012e194e91b6cd0bbd25d29d1e: 5. Ban on importation Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended— in the third sentence of subsection (a), by inserting...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Trade, Agriculture
Primary Purpose
This bill, To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Hawley introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology